IFRX
InflaRx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Negative Gross Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IFRX
Inflarx N.V.
A clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system
Winzerlaer Str. 2, 07745 Jena, Germany
--
InflaRx N.V. was incorporated under the laws of the Netherlands in June 2017 and is a holding company of InflaRx GmbH under the terms of the corporate restructuring. The company is a clinical-stage biopharmaceutical company focused on applying its unique anti-C5a technology to discover and develop a primary, potent and specific inhibitor of a complementary activator called C5a. C5a is a powerful inflammatory mediator involved in the progression of a variety of autoimmune and inflammatory diseases.
Company Financials
EPS
IFRX has released its 2025 Q1 earnings. EPS was reported at -0.13, versus the expected -0.20421, beating expectations. The chart below visualizes how IFRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IFRX has released its 2025 Q3 earnings report, with revenue of 27.96K, reflecting a YoY change of -79.74%, and net profit of -14.39M, showing a YoY change of 26.01%. The Sankey diagram below clearly presents IFRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
